Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jgar.2018.01.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ciprofloxacin-susceptible but levofloxacin-resistant Pseudomonas aeruginosa clinical strains with Vitek2: which mechanism involved and consequences in case of fluoroquinolone treatment?
Eur J Clin Microbiol Infect Dis
December 2024
Service de Bactériologie et des Contrôles Microbiologiques, CHU Nantes, Nantes, France.
Purpose: Pseudomonas aeruginosa clinical strains isolated harbored sometimes an atypical phenotype using the automated Vitek2: ciprofloxacin-susceptibility but levofloxacin-resistance according to 2019 CA-SFM criteria. The aims of this study are to investigate the resistance mechanism(s) involved and to identify the consequences on fluoroquinolone treatment.
Methods: Strain resistance profile, patient's data were recovered and reviewed from the database.
In vitro activity of delafloxacin against clinical levofloxacin-resistant Helicobacter pylori isolates.
J Antimicrob Chemother
October 2024
Bacteriology Laboratory, Infectious Agents Department, CHU de Poitiers, 2 rue de la Milétrie, 86021 Poitiers, France.
Background: Increasing antibiotic resistance in Helicobacter pylori necessitates research on new active molecules. In 2017, delafloxacin, a new fluoroquinolone with chemical properties of activity under acidic conditions, was approved for treatment of community-acquired bacterial pneumonia and acute bacterial skin and soft-tissue infections. Mutations in gyrA are responsible for fluoroquinolone resistance, but certain clinical isolates of H.
View Article and Find Full Text PDFTwo cases of iatrogenic levofloxacin-resistant pre-XDR tuberculosis in Japan.
J Infect Chemother
August 2024
The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, 3-1-24 Matsuyama, Kiyose, Tokyo, 204-8522, Japan; Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, 3-1-24 Matsuyama, Kiyose, Tokyo, 204-8522, Japan.
This case report discusses two instances of iatrogenically induced pre-extensively drug-resistant tuberculosis (pre-XDR TB). In both cases, the patients were initially diagnosed with tuberculosis and hospitalized in university hospitals. Nucleic acid amplification tests identified rifampicin-resistant tuberculosis, leading to a deviation from clinical guidelines.
View Article and Find Full Text PDFEffective strategies for managing trimethoprim-sulfamethoxazole and levofloxacin-resistant Stenotrophomonas maltophilia infections: bridging the gap between scientific evidence and clinical practice.
Curr Opin Infect Dis
December 2024
Médecine Intensive Réanimation, Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne-Université, Hôpital Pitié-Salpêtrière.
Article Synopsis
- The review outlines challenges in treating difficult-to-treat strains of Stenotrophomonas maltophilia (Sma), particularly those resistant to standard antibiotics like trimethoprim-sulfamethoxazole and fluoroquinolones.
- Recent findings indicate that current antibiotic breakpoints may underestimate the prevalence of these resistant strains, highlighting the need for better treatment strategies.
- While cefiderocol and an aztreonam-L2 inhibitor combination show promise, their clinical efficacy is still uncertain, and further comparative studies are essential to guide treatment decisions effectively.*
Genetic Markers of Resistance to Clarithromycin and Levofloxacin in Moscow, Russia.
Curr Issues Mol Biol
June 2024
A.S. Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia.
Article Synopsis
- * A study evaluated a new Sanger sequencing test on 25 pure culture samples, showing 100% sensitivity for clarithromycin and high sensitivity (93%) and specificity (92%) for levofloxacin resistance detection.
- * In clinical tests on 112 patients, resistance mutations were found in 24% for clarithromycin and 23% for levofloxacin, with specific mutations identified, emphasizing the importance of personalized therapy to combat antibiotic resistance.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!